COVID-19 Seroprevalence in Pregnant Women and Blood Donors

The study aims to measure the SARS-CoV-2 seroprevalence (ie. the proportion of people with antibodies against the virus) in pregnant women and blood donors in an administrative area of France, and to determine whether these measures are representative of the general population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Respiratory Infection

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de besançon

Besançon, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pregnant women

Adult female
Admitted to hospital for live birth
Informed consent
Affiliated to the French social security health insurance scheme
Blood donors

Adult male or female
Qualified for whole blood donation (up to 70 years old in France)
Informed consent
Affiliated to the French social security health insurance scheme

Exclusion criteria

Legal incapacity or limited legal capacity
Subject without health insurance coverage
Exclusion period of another study or exclusion period of the French national healthy volunteer registry

Treatment and study plan

Primary outcomes

Anti-SARS-CoV-2 spike protein total IgG

Time frame: at inclusion

Total IgG directed against anti-SARS-CoV-2 spike protein as measured by ELISA assay

Secondary outcomes

Anti-SARS-CoV-2 nucleocapsid protein total IgG

Time frame: at inclusion

Total IgG directed against anti-SARS-CoV-2 nucleocapsid protein as measured by ELISA assay

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Official study title

SARS-CoV-2 sERoprévalences Dans la Population Des Femmes Enceintes et Donneurs de Sang

Acronym: CoVERED

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: May 19, 2021
Registry last updated: Oct 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed